CURE - Oncology & Cancer News for Patients & Caregivers
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
Top 5 Cancer Vaccine Stories from 2024 - curetoday.com
1 day ago · Personalized cancer vaccines may be available by 2025, with mRNA-4157 showing promising results in melanoma treatment. ELI-002 offers a novel approach for pancreatic cancer but is several years from broad availability. mRNA-4157 could become the first approved cancer vaccine with clear efficacy ...
Top FDA Approvals of Oncology Therapies in 2024
3 days ago · Throughout 2024, the Food and Drug Administration (FDA) approved many cancer treatments, benefitting patients with different types of cancer. CURE compiled a list of the top FDA approval stories throughout the year, with diseases including gynecologic cancer, breast cancer, multiple myeloma and pancreatic cancer, among others.
Real-World Data May Confirm Monjuvi’s Efficacy in Large B-Cell …
2 days ago · The real-world effectiveness of Monjuvi (tafasitamab-cxix) in U.S. patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was confirmed, along with factors associated with survival, according to data from a retrospective medical chart review presented at the 2024 ASH Annual Meeting.. At a median follow-up time of 14.7 months from Monjuvi initiation, the real-world ...
FDA Grants Breakthrough Therapy Designation to Trodelvy for …
3 days ago · Trodelvy is currently indicated in the United States for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies and unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in ...
All News - Curetoday
CURE®s’ news page brings patients, survivors, and caregivers everything they need to know when it comes to cancer news and important oncology updates.
FDA Approves Braftovi Plus Erbitux and Chemo for Metastatic …
6 days ago · FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer. BREAKWATER trial showed a 61% objective response rate for the treatment group versus 40% for the control group. Median duration of response was 13.9 months for the treatment group compared to ...
About Us - Curetoday
3 days ago · Launched in 2002 for patients with cancer, survivors and their caregivers, CURE® Media Group’s flagship magazine and online resource curetoday.com provide access to leading resources and information that serve as a guide to every stage of the cancer experience.
6 FDA Cancer Approvals from August 2024 - Curetoday
In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.
Long-Term Study Data Support Keytruda as Standard of Care for …
Oct 1, 2024 · A 10-year follow-up data from the KEYNOTE-006 study showed that Keytruda continued to outperform Yervoy in terms of overall survival, progression-free survival, and melanoma-specific survival for patients with advanced melanoma.